/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Xencor Inc Share Price Today: Live Updates & Key Insights

Xencor Inc share price today is $11.62, up -3.57%. The stock opened at $11.6 against the previous close of $12.04, with an intraday high of $11.74 and low of $11.27.

Xencor Inc Share Price Chart

style
pb-0

Xencor Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Xencor Inc Share Price Performance

$11.62 -0.0357(-3.57%) XNCR at 13 Mar 2026 03:58 PM Biotechnology
Lowest Today 11.27
Highest Today 11.74
Today’s Open 11.6
Prev. Close 12.04
52 Week High 18.69
52 Week Low 6.92
Day’s Range: Low 11.27 High 11.74
52-Week Range: Low 6.92 High 18.69
1 day return -
1 Week return +2.83
1 month return +0.51
3 month return -30.81
6 month return +36.62
1 year return -9.78
3 year return -59.11
5 year return -75.04
10 year return -

Xencor Inc Institutional Holdings

BlackRock Inc 16.10

PRIMECAP Management Company 13.93

Vanguard Group Inc 9.77

Bvf Inc 9.73

RTW INVESTMENTS, LLC 9.24

PRIMECAP Odyssey Aggressive Growth 8.65

iShares Core S&P Small-Cap ETF 5.93

State Street Corp 5.01

EcoR1 Capital, LLC 4.43

PRIMECAP Odyssey Growth 4.29

TCG Crossover Management, LLC 3.34

Vanguard Total Stock Mkt Idx Inv 3.04

Geode Capital Management, LLC 2.36

iShares Russell 2000 ETF 2.34

T. Rowe Price Associates, Inc. 2.31

State Street® SPDR® S&P® Biotech ETF 2.21

Defilade Capital Management, L.P. 1.93

Legal & General Group PLC 1.78

Dimensional Fund Advisors, Inc. 1.70

UBS Group AG 1.60

Baker Bros Advisors LP 1.50

The Goldman Sachs Group Inc 1.39

Morgan Stanley - Brokerage Accounts 1.23

Vanguard Small Cap Index 1.11

JPMorgan Chase & Co 1.09

Vanguard Institutional Extnd Mkt Idx Tr 1.05

Bank of America Corp 1.03

Johnson & Johnson 1.02

Vanguard US Opportunities Ins USD Acc 1.00

iShares S&P Small-Cap 600 Value ETF 0.95

Fidelity Small Cap Index 0.94

State Street SPDR Port S&P 600 Sm CpETF 0.90

iShares Russell 2000 Value ETF 0.83

T. Rowe Price Integrated US SmCapGrEq 0.80

T. Rowe Price Integrated US Sm Gr Eq 0.80

iShares Biotechnology ETF 0.69

Vanguard Tax-Managed Small Cap Adm 0.65

Vanguard Small Cap Growth Index Inv 0.61

State St Russell Sm/Mid Cp® Indx SL Cl I 0.55

T. Rowe Price Health Sciences 0.55

Xencor Inc Market Status

Strong Buy: 8

Buy: 3

Hold: 0

Sell: 1

Strong Sell: 0

Xencor Inc Fundamentals

Market Cap 883.00 M

PB Ratio 1.3893

PE Ratio 0.0

Enterprise Value 523.01 M

Total Assets 875.50 M

Volume 1137841

Xencor Inc Company Financials

Annual Revenue FY25:125576000 125.6M, FY24:168338000 168.3M, FY23:145259000 145.3M, FY22:164579000 164.6M, FY21:275111000 275.1M

Annual Profit FY25:115064000 115.1M, FY24:-85260000 -85.3M, FY23:null 0.0M, FY22:164579000 164.6M, FY21:275111000 275.1M

Annual Net worth FY25:-91923000 -91.9M, FY24:-126087000 -126.1M, FY23:-119028000 -119.0M, FY22:-55181000 -55.2M, FY21:82631000 82.6M

Quarterly Revenue Q4/2025:28237000 28.2M, Q3/2025:20999000 21.0M, Q2/2025:43608000 43.6M, Q1/2025:32732000 32.7M, Q4/2024:10710000 10.7M

Quarterly Profit Q4/2025:25660000 25.7M, Q3/2025:20999000 21.0M, Q2/2025:40955000 41.0M, Q1/2025:30039000 30.0M, Q4/2024:10710000 10.7M

Quarterly Net worth Q4/2025:-6653000 -6.7M, Q3/2025:-6027000 -6.0M, Q2/2025:-30825000 -30.8M, Q1/2025:-48418000 -48.4M, Q4/2024:-45143000 -45.1M

About Xencor Inc & investment objective

Company Information Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Organisation Biotechnology

Employees 260

Industry Biotechnology

CEO Dr. Bassil I. Dahiyat Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow